These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 27127153)

  • 21. Phase II study of ifosfamide, carboplatin, etoposide and GM-CSF in small cell lung cancer.
    Thongprasert S
    J Med Assoc Thai; 2000 May; 83(5):549-53. PubMed ID: 10863902
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Experience of a German multicenter study group with ifosfamide in small cell lung cancer.
    Havemann K; Wolf M; Drings P; Hans K; Schroeder M; Holle R; Flechtner H; Goerg R; Becker H
    Semin Oncol; 1989 Feb; 16(1 Suppl 3):9-18. PubMed ID: 2539648
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined ifosfamide, etoposide and oxalipatin chemotherapy, a low-toxicity regimen for first-relapsed or refractory Hodgkin lymphoma after ABVD/EBVP: a prospective monocentre study on 34 patients.
    Sibon D; Ertault M; Al Nawakil C; de Bazelaire C; Franchi P; Brière J; de Kerviler E; Beranger N; Thieblemont C; Brice P
    Br J Haematol; 2011 Apr; 153(2):191-8. PubMed ID: 21385169
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ifosfamide, etoposide, cytarabine, and methotrexate as salvage chemotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
    Stamatoullas A; Fruchart C; Bastit D; Boulet D; Moncondult M; Piguet H; Tilly H
    Cancer; 1996 Jun; 77(11):2302-7. PubMed ID: 8635099
    [TBL] [Abstract][Full Text] [Related]  

  • 25. DICE (dexamethasone, ifosfamide, cisplatin, etoposide) infusional chemotherapy for refractory or relapsed non-Hodgkin's lymphoma (NHL).
    Coleman M; Leonard J; Shuster MW; Kaufman TP
    Eur J Haematol Suppl; 2001 Jul; 64():41-5. PubMed ID: 11486401
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ifosfamide, carboplatin and etoposide (ICE) as second-line regimen alone and in combination with regional hyperthermia is active in chemo-pre-treated advanced soft tissue sarcoma of adults.
    Fiegl M; Schlemmer M; Wendtner CM; Abdel-Rahman S; Fahn W; Issels RD
    Int J Hyperthermia; 2004 Sep; 20(6):661-70. PubMed ID: 15370821
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group.
    Schmoll HJ; Kollmannsberger C; Metzner B; Hartmann JT; Schleucher N; Schöffski P; Schleicher J; Rick O; Beyer J; Hossfeld D; Kanz L; Berdel WE; Andreesen R; Bokemeyer C;
    J Clin Oncol; 2003 Nov; 21(22):4083-91. PubMed ID: 14568987
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neoadjuvant etoposide, ifosfamide, and cisplatin for the treatment of olfactory neuroblastoma.
    Kim DW; Jo YH; Kim JH; Wu HG; Rhee CS; Lee CH; Kim TY; Heo DS; Bang YJ; Kim NK
    Cancer; 2004 Nov; 101(10):2257-60. PubMed ID: 15484215
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lomustine (chloroethylnitrosourea [CCNU]), ifosfamide, bleomycin, vincristine, and cisplatin (CIBO-P) is an effective regimen for patients with poor prognostic refractory or multiple disease recurrent aggressive non-Hodgkin lymphoma.
    Musolino A; Perrone MA; Michiara M; Delnevo D; Franciosi V; Di Blasio B; Ceci G; Camisa R; Ardizzoni A; Cocconi G
    Cancer; 2005 May; 103(10):2109-17. PubMed ID: 15803492
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Concomitant administration of vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for high-risk sarcomas: the St. Jude Children's Research Hospital experience.
    Navid F; Santana VM; Billups CA; Merchant TE; Furman WL; Spunt SL; Cain AM; Rao BN; Hale GA; Pappo AS
    Cancer; 2006 Apr; 106(8):1846-56. PubMed ID: 16541446
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase II study of ifosfamide, cisplatin, etoposide in patients with advanced non-small cell lung cancer: a preliminary report.
    Shepherd FA; Goss PE; Latreille J; Stewart D; Logan D; Evans WK; Maroun J; Warner E
    Semin Oncol; 1990 Apr; 17(2 Suppl 4):19-23. PubMed ID: 2159185
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pilot study of ambulatory infusional delivery of a multidrug regimen: ifosfamide, carboplatin and etoposide (ICE).
    Lokich J; Anderson N; Moore C; Bern M; Coco F; Dow E
    J Infus Chemother; 1996; 6(1):39-42. PubMed ID: 8748006
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rhabdomyosarcoma in adults: analysis of treatment modalities in a prospective single-center series.
    Bergamaschi L; Bertulli R; Casanova M; Provenzano S; Chiaravalli S; Gasparini P; Collini P; Sangalli C; Gandola L; Diletto B; Morosi C; Fiore M; Massimino M; Ferrari A
    Med Oncol; 2019 May; 36(7):59. PubMed ID: 31104202
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical results of high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation in children with advanced stage rhabdomyosarcoma.
    Kim NK; Kim HS; Suh CO; Kim HO; Lyu CJ
    J Korean Med Sci; 2012 Sep; 27(9):1066-72. PubMed ID: 22969254
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Platinum-Based Regimens Are Active in Advanced Pediatric-Type Rhabdomyosarcoma in Adults and Depending on HMGB1 Expression.
    Hindi N; Carrillo-García J; Blanco-Alcaina E; Renshaw M; Luna P; Durán J; Jiménez N; Sancho P; Ramos R; Moura DS; Martín-Broto J
    Int J Mol Sci; 2023 Jan; 24(1):. PubMed ID: 36614297
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [A case of advanced rhabdomyosarcoma of the spermatic cord who occurred epilepsy-like symptoms, but was completely responded to chemotherapy].
    Suzuki K; Kobayashi M; Tokue A
    Nihon Hinyokika Gakkai Zasshi; 2004 Jul; 95(5):733-7. PubMed ID: 15354722
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chemotherapy-induced differentiation to cure botryoid rhabdomyosarcoma: a case report and review of the literature.
    Assi T; El Rassy E; Abi-Tayeh G; Sader-Ghorra C; Abadjian G; Eid R; Moussa T; Farhat F; Kattan J
    Eur J Gynaecol Oncol; 2017; 38(2):323-325. PubMed ID: 29953806
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transitioning ifosfamide chemotherapy regimens to the ambulatory setting: reviewing cost savings and safety profile.
    Banh C; Valsvik K; Arredondo A; Notbohm K; Elquza E; Babiker H; Kraft A; Boiles AR; Persky D; Ortega A; McBride A
    Support Care Cancer; 2022 Mar; 30(3):2755-2766. PubMed ID: 34825982
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hypophosphataemic rickets after ifosfamide treatment in children.
    Skinner R; Pearson AD; Price L; Cunningham K; Craft AW
    BMJ; 1989 Jun; 298(6687):1560-1. PubMed ID: 2503116
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.